Fulgent Genetics stock price surges as 15min chart indicates bullish KDJ Golden Cross

Fulgent Genetics' 15-minute chart has recently exhibited a bullish trend, marked by the occurrence of a KDJ Golden Cross and a Bullish Marubozu at 04/21/2025 14:45. This indicates a shift in momentum towards the upside, suggesting that the stock price may continue to rise in the near future. The strong buying interest in the stock is evident, and the market is likely to remain under the control of buyers. As a result, the bullish momentum is expected to persist, making it an attractive time to consider purchasing Fulgent Genetics' stock.

Fulgent Genetics, Inc. (NASDAQ: FLGT) has exhibited a notable bullish trend in its 15-minute chart, with the occurrence of a KDJ Golden Cross and a Bullish Marubozu at 04/21/2025 14:45. This technical indicator combination suggests a shift in momentum towards the upside, indicating potential continued stock price appreciation in the near future. The strong buying interest in the stock is evident, and the market appears to be under the control of buyers, reinforcing the bullish momentum [1].

Institutional investors have also shown increased interest in Fulgent Genetics. Inlight Wealth Management LLC purchased 37,088 shares in the fourth quarter, valued at approximately $685,000, increasing their ownership to 0.12% of the company [1]. Other institutional investors, such as GAMMA Investing LLC, Exchange Traded Concepts LLC, Centiva Capital LP, Federated Hermes Inc., and Russell Investments Group Ltd., have also modified their holdings in Fulgent Genetics, with notable increases in their stakes [1].

The stock's performance has been mixed, with a mid-day trading decrease of $0.38 on 04/21/2025, reaching $18.70. However, the 50-day moving average is $17.00, and the 200-day moving average is $18.27, suggesting a steady upward trend [1]. The company's market capitalization is $577.19 million, with a P/E ratio of -3.39 and a beta of 1.36 [1].

Analysts have provided varying opinions on Fulgent Genetics. StockNews.com raised its rating from "sell" to "hold," while Piper Sandler reduced its target price from $22.00 to $16.00, setting a "neutral" rating [1]. Additionally, insider activity has been significant, with CFO Paul Kim purchasing 100,000 shares, representing a 40.28% increase in his ownership [1].

Fulgent Genetics provides clinical diagnostic and therapeutic development solutions to physicians and patients, with a focus on molecular diagnostic testing, genetic testing, and other specialized services. The company's strong institutional backing and recent technical indicators suggest a favorable outlook for investors considering Fulgent Genetics' stock [1].

References:

[1] https://www.marketbeat.com/instant-alerts/37088-shares-in-fulgent-genetics-inc-nasdaqflgt-purchased-by-inlight-wealth-management-llc-2025-04-11/